X

Trial Profile

A European compassionate use and named patient basis for the treatment of neuroendocrine tumours

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 Nov 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
Indications Neuroendocrine tumours
Focus Expanded access; Therapeutic Use

Most Recent Events

17 Nov 2017 According to an Advanced Accelerator Applications media release, in an compassionate program 1857 patients were participating from 67 centres in Europe.
31 Aug 2017 According to an Advanced Accelerator Applications media release, an European compassionate program were participating 1800 patients from 62 centres at 31 July 2017.
25 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com